Cresemba is owned by Astellas.
Cresemba contains Isavuconazonium Sulfate.
Cresemba has a total of 4 drug patents out of which 0 drug patents have expired.
Cresemba was authorised for market use on 06 March, 2015.
Cresemba is available in capsule;oral dosage forms.
Drug patent challenges can be filed against Cresemba from 2026-03-06.
The generics of Cresemba are possible to be released after 14 September, 2027.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(2 years from now) | |
US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(4 years from now) | |
US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 6, 2020 |
ODE* (ODE*) | Mar 6, 2022 |
Orphan Drug Exclusivity (ODE) | Mar 6, 2022 |
Generating Antibiotic Incentives Now (GAIN) | Mar 6, 2027 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 2026-03-06
Market Authorisation Date: 06 March, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
65
United States
15
Japan
15
European Union
13
China
12
Korea, Republic of
1
Canada
1
Germany
1
Australia
1
Denmark
1
Austria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic